Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor and an Antineoplastic agent.
Indication
In combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
As a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
